REVIEW SERIES

Past, present and future therapeutic approaches in nodal peripheral T-cell lymphomas

Henry S. Ngu˚ and Kerry J. Savage

Center for Lymphoid Cancer, Division of Medical Oncology BC Cancer and the University of British Columbia, British Columbia, Vancouver, Canada

˚*Current address: Department of Hematology, Auckland City Hospital, Auckland, New Zealand*

Correspondence: K.J. Savage
ksavage@bccancer.bc.ca

Received: May 18, 2023.
Accepted: August 14, 2023.

https://doi.org/10.3324/haematol.2021.280275

Treatment	Site	PTCL type	Phase	Study	Status Preliminary report
Treatment naive					
CHO(E)P + duvelisib or azacitidine	U.S Alliance	PTCL-NOS, TFHL	2	NCT04803201	Recruiting
Auto-SCT vs observation TRANSCRIPT study	Europe	Nodal PTCLs except ALK-positive	3 CR only	NCT05444712	Recruiting
Chidamide + CHOP untreated TFHLs	China	TFHL	2	NCT05572983	Recruiting
Chidamide + CHOP in untreated AITL	China	AITL	2	NCT03853044	Active, not recruiting
CHOP vs CHOP + targeted combination[a]	China	All PTCLs	2, parallel	NC504480099	Active, not recruiting
CHOP + lenalidomide vs CHOP in untreated PTCL	China	PTCL	2	NCT04922567	Recruiting
Azacitidine + chidamide CHOP vs CHOP	China	TFHL	3	NCT05678933	Enrolling, by invitation
CHP + brentuximab vodoin	U.S.	PTCL-NOS/TFHL CD30 < 10%[d]	Phase2	NCT04569032	Recruiting
CHOP + golidocitinib	China	All PTCLs	Phase 2	NCT05963347	Not yet recruiting
Relapsed Refractory					
Novel agents and combination therapies					
Azacitidine vs investigator's choice [b]	Japan	AITL	3	NCT03703375	Not recruiting
Romidepsin + azacitadine vs investigator's choice[c]	U.S.	PTCL	2B (R)	NCT04747236	Recruiting
Pembrolizumab + pralatrexate	U.S.	All PTCL	1/2	NCT03598998	Recruiting
Valemetostat (EZH1 dual inhibitor)	Global	All PTCL	2	NCT04703192	Not recruiting
Lacutamab (anti-KIR3DL2 antibody) + GemOx (LARO)	U.S.	KIR3DL2 + PTCL	2	NCT04984837	Recruiting
Golidocitinib[1] **(2nd generation JAK1 inhibitor) (JACKPOT8)**	S. Korea	All PTCL	1/2	NCT04105010	Recruiting
Tolinapant (dual IAP	Global	All PTCL	1/2	NCT05403450	Recruiting

antagonist) + Decitabine/Cedazuridine					
Nanatinostat + valganciclovir (NAVAL-1)	Global	EBV+ lymphomas	2	NCT0501058	Recruiting
Cellular therapies					
CD30 CART-cell (UNC-Lineberger Comprehensive Cancer Center)	U.S. UNC-Lineberger Comprehensive Cancer Center	CD30+ PTCL	2	NCT04083495	Recruiting
CD30 CAR-T-cell (RELY-30) Baylor	U.S.	CD30+ PTCL	1	NCT02917083	Recruiting
Autologous CART-cell CD30 with CCR4 (ATL.CD30.CCR4) +/- ATL CAR.CD30 (UNC)	U.S.	CTCL Primary cut CD30 LPD	1	NCT03602157	Recruiting
AFM13 CD16/CD30 bispecific antibody[2] (REDIRECT)	Global	PTCL tMF	2	NCT04101331	Not recruiting
CTX130 CD70-directed allogeneic T cell (COBALT-LIM)	Global	PTCL or BCL	1	NCT04502446	Recruiting
AUTO4 in TRBC1 positive T-cell lymphoma[3]	U.K.	PTCL TRBC1 + (PTCL-NOS, AITL, ALCL)	1/2	NCT03590574	Recruiting
CART-cell in CD5 + T-cell lymphomas (MAGENTA)[4]	U.S. Baylor	CD5+ TCL	1	NCT03081910	Recruiting

Supplemental Table 1: Select ongoing clinical trials that include nodal PTCL

[a]Excludes ALK+ALCL, extranodal NK/T-cell lymphoma, ATLL, T-LGL

[b]Investigator's choice romidepsin, gemcitabine: Note as of February 2023, study was active but not recruiting

LARO Lymphoma Academic Research Organization R randomized

[c] Investigator's choice belinostat, pralatrexate, gemcitabine

[d] Also includes ATLL, EATL, HSTCL, MEITCL, indolent T-cell lymphproliferative disorder of the GI tract

1. Kim W-S, Yoon D-H, Song Y, et al. S218: A Phase I/II Study of Golidocitinib, a Selective JAK1 Inhibitor, In Refractory Or Relapsed Peripheral T Cell Lymphoma. Hemasphere 2022;6119–120.
2. Sawas A, Elgedawe H, Vlad G, et al. Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202). Blood 2018;132(Supplement 1):2908–2908.
3. Cwynarski K, Iacoboni G, Tholouli E, et al. First in Human Study of AUTO4, a TRBC1-Targeting CAR T-Cell Therapy in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma. Blood 2022;140(Supplement 1):10316–10317.
4. Hill L, Rouce RH, Smith TS, et al. CD5 CAR T-Cells for Treatment of Patients with Relapsed/Refractory CD5 Expressing T-Cell Lymphoma Demonstrates Safety and Anti-Tumor Activity. Biology of Blood and Marrow Transplantation 2020;26(3):S237.